Overview

Treatment of Patients With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before, Under and After Radiation and With Adding Cetuximab to K-RAS Wild-type Patients

Status:
Unknown status
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
response rate to adding cetuximab, oxaliplatin and capecitabine to radiation for advanced rectum cancer
Phase:
Phase 2
Details
Lead Sponsor:
Copenhagen University Hospital at Herlev
Treatments:
Capecitabine
Cetuximab
Oxaliplatin